Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | ADM2 | Q7Z4H4 | 9/20 | 0.41 |
| ▸ | CALCRL | Q16602 | 10/20 | 0.40 |
| ▸ | CALCB | P10092 | 8/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2192451 | 0.88 | CALCRL (0.41) | ADM2CALCRLCALCB | |
| SCHEMBL1285788 | 0.85 | ADM2 (0.41) | ADM2CALCRLCALCB | |
| SCHEMBL13906420 | 0.78 | ADM2 (0.50) | ADM2CALCRLCALCB | |
| SCHEMBL3036259 | 0.76 | ADM2 (0.50) | ADM2CALCRLCALCB | |
| Hydrochloric Acid SCHEMBL548949 | 0.75 | ADM2 (0.49) | ADM2CALCRLCALCB | |
| SCHEMBL3040463 | 0.74 | ADM2 (0.48) | ADM2CALCRLCALCB | |
| SCHEMBL549047 | 0.74 | ADM2 (0.48) | ADM2CALCRLCALCB | |
| SCHEMBL3036260 | 0.74 | ADM2 (0.48) | ADM2CALCRLCALCB | |
| SCHEMBL1744295 | 0.73 | CALCRL (0.43) | ADM2CALCRLCALCB | |
| SCHEMBL14978098 | 0.73 | CALCRL (0.46) | ADM2CALCRLCALCB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2379529-B1 | CGRP-ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2015-06-10 | — | — | EP | disclosed |
| US-8952014-B2 | Pyrimidine derivatives which are CGRP—antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-02-10 | — | — | US | disclosed |
| US-8952014-B2 | Pyrimidine derivatives which are CGRP—antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-02-10 | — | — | US | disclosed |
| US-8952014-B2 | Pyrimidine derivatives which are CGRP—antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-02-10 | — | — | US | disclosed |
| US-20120088755-A1 | Novel Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-04-12 | — | — | US | disclosed |
| US-20120088755-A1 | Novel Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-04-12 | — | — | US | disclosed |
| US-20120088755-A1 | Novel Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-04-12 | — | — | US | disclosed |
| WO-2010070022-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088755-A1 | Novel Compounds | SLC26A4, F12, SLCO1B3 | SYK 4533/4885ADM2 1191/4885CALCRL 501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.